Business Context and Reporting Period
Company: pSivida Limited (Note: Metadata listed "Eyepoint, Inc." but filing text confirms registrant is pSivida Limited).
Filing Type: Form 10-Q (Quarterly Report).
Period: Three and six months ended December 31, 2007.
Business Overview: pSivida is a global drug delivery company focused on the biomedical sector. Key assets include Retisert and Vitrasert (licensed to Bausch & Lomb), Medidur FA for DME (in Phase III trials with Alimera Sciences), and BioSilicon/BrachySil (oncology applications). The company transitioned its primary accounting basis from A-IFRS to U.S. GAAP effective September 30, 2007.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended Dec 31, 2007 | Six Months Ended Dec 31, 2006 |
|---|---|---|
| Total Revenues | $231 | $1,114 |
| Net Loss | $(6,590) | $(31,059) |
| Operating Expenses | $13,480 | $17,932 |
| Cash and Cash Equivalents (End of Period) | $9,783 | $4,216 |
| Net Cash Used in Operating Activities | $(11,174) | $(11,361) |
| Net Cash Provided by Financing Activities | $18,387 | $4,449 |
| Total Assets | $107,670 | $102,504 |
| Accumulated Deficit | $(155,457) | $(148,867) |
Debt and Liquidity: The company had no borrowings or lines of credit as of December 31, 2007. Current assets ($13.1M) exceeded current liabilities ($11.2M), resulting in net current assets of $1.96M. However, the company maintains a significant accumulated deficit and relies on external financing.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 79% to $231,000 for the six months ended Dec 31, 2007, compared to $1.1M in the prior year. This was driven by a $451,000 decrease in royalty income from Bausch & Lomb (due to royalty retention agreements) and a $432,000 reduction in collaborative research revenue.
- Net Loss Improvement: Net loss decreased significantly by 79% to $6.6M from $31.1M. The prior year loss included a $12.1M loss on extinguishment of debt and $2.4M in registration rights penalties, neither of which occurred in the current period.
- Operating Expenses: Total operating expenses decreased 25% to $13.5M. Research and Development (R&D) expenses dropped 28% primarily due to reduced amortization of intangible assets following a $45.3M impairment write-down in June 2007 and cost reduction measures in the U.K. and Singapore.
- Derivative Income: The company recognized $6.0M in income from the change in fair value of derivative liabilities (warrants denominated in Australian dollars), compared to $2.1M in the prior year. This non-cash gain significantly offset operating losses.
- Capital Raise: In July 2007, the company raised net proceeds of $18.4M through the sale of shares and warrants, including a purchase by Pfizer. This increased cash balances from $2.7M to $9.8M.
Outlook, Risks, and Management Commentary
- Liquidity and Going Concern: Management states that existing cash, expected funding from Pfizer ($2M annually starting 2008), and a $1.5M note receivable from the sale of AION Diagnostics will fund operations through at least September 30, 2008. However, additional funding is required before June 30, 2008, to maintain current operations and development plans. Failure to raise capital could force a significant scaling back of operations.
- Revenue Constraints: The company does not expect to receive Retisert royalty income from Bausch & Lomb through at least the fiscal year ending June 30, 2008, as royalties are being retained to offset a prior advance.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of December 31, 2007. A material weakness was identified regarding inadequate accounting personnel to handle complex transactions, though remediation efforts (hiring and consolidation) are underway.
- Subsequent Event: In January 2008, the company sold and licensed BioSilicon intellectual property to Intrinsiq Materials for an initial $500,000 plus potential future royalties totaling $3.95M over five years.
- Risks: Key risks include dependence on external capital, uncertainty of product development and regulatory approval, and the potential for further impairment of goodwill and intangible assets if projected cash flows are not met.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $9.8M cash balance against the stated need for additional financing before June 30, 2008.
- Derivative Volatility: Assess the impact of future share price fluctuations on the $3.4M derivative liability, which caused significant non-cash income in the current period.
- Royalty Retention: Confirm the timeline for the release of Retisert royalties currently held by Bausch & Lomb.
- Internal Control Remediation: Monitor progress on hiring accounting personnel and consolidating functions to resolve the material weakness in internal controls.
- Collaboration Funding: Track the commencement of the $2M annual funding from Pfizer and the collection of the $1.5M note receivable from GEM Global Yield Fund.